HK1146822A1 - Kappa selective opioid receptor antagonist kappa - Google Patents

Kappa selective opioid receptor antagonist kappa

Info

Publication number
HK1146822A1
HK1146822A1 HK11100691.9A HK11100691A HK1146822A1 HK 1146822 A1 HK1146822 A1 HK 1146822A1 HK 11100691 A HK11100691 A HK 11100691A HK 1146822 A1 HK1146822 A1 HK 1146822A1
Authority
HK
Hong Kong
Prior art keywords
kappa
receptor antagonist
opioid receptor
selective opioid
selective
Prior art date
Application number
HK11100691.9A
Other languages
English (en)
Inventor
Buezo Nuria Diaz
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1146822A1 publication Critical patent/HK1146822A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK11100691.9A 2008-01-22 2011-01-24 Kappa selective opioid receptor antagonist kappa HK1146822A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (1)

Publication Number Publication Date
HK1146822A1 true HK1146822A1 (en) 2011-07-15

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100691.9A HK1146822A1 (en) 2008-01-22 2011-01-24 Kappa selective opioid receptor antagonist kappa

Country Status (33)

Country Link
US (2) US7709522B2 (es)
EP (1) EP2252581B1 (es)
JP (1) JP5345637B2 (es)
KR (1) KR101172170B1 (es)
CN (1) CN101925576B (es)
AR (1) AR070158A1 (es)
AU (1) AU2009206653B2 (es)
BR (1) BRPI0907382B8 (es)
CA (1) CA2713025C (es)
CO (1) CO6290644A2 (es)
CY (1) CY1113071T1 (es)
DK (1) DK2252581T3 (es)
DO (1) DOP2010000222A (es)
EA (1) EA017484B1 (es)
EC (1) ECSP10010365A (es)
ES (1) ES2388708T3 (es)
HK (1) HK1146822A1 (es)
HR (1) HRP20120558T1 (es)
IL (1) IL206038A (es)
JO (1) JO2797B1 (es)
MA (1) MA32751B1 (es)
MX (1) MX2010007849A (es)
MY (1) MY163014A (es)
NZ (1) NZ586225A (es)
PE (1) PE20091317A1 (es)
PL (1) PL2252581T3 (es)
PT (1) PT2252581E (es)
SI (1) SI2252581T1 (es)
TN (1) TN2010000306A1 (es)
TW (1) TWI422369B (es)
UA (1) UA100715C2 (es)
WO (1) WO2009094260A1 (es)
ZA (1) ZA201003908B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2712347A1 (en) * 2008-01-22 2009-07-30 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
EP2252581B1 (en) * 2008-01-22 2012-06-20 Eli Lilly And Company Kappa selective opioid receptor antagonist
WO2013040321A1 (en) * 2011-09-15 2013-03-21 University Of Kansas Kappa opioid receptor effectors and uses thereof
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
CA2858752C (en) 2011-12-09 2019-12-31 Research Triangle Institute 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
AU2014268361B2 (en) * 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP4141001A1 (en) 2017-03-17 2023-03-01 The Scripps Research Institute Kappa opioid receptor antagonists and products and methods related thereto
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3219079A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023206048A1 (en) * 2022-01-10 2024-08-29 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭(aticaprant)之形式
TW202345795A (zh) * 2022-03-07 2023-12-01 美商健生醫藥公司 純質形式之結晶型阿替卡普蘭
US20230277500A1 (en) * 2022-03-07 2023-09-07 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
BR0010495A (pt) * 1999-05-12 2002-02-13 Hoffmann La Roche Derivado da imidazodiazepina
AU2001292164A1 (en) * 2000-10-05 2002-04-15 Hanns Mohler Selective anxiolytic therapeutic agents
AU2002231206A1 (en) 2000-12-21 2002-07-01 The Mclean Hospital Corporation Treatment of depression
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
AU2003230754B2 (en) * 2002-03-28 2007-10-25 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
DE60321207D1 (en) 2002-09-19 2008-07-03 Lilly Co Eli Diaryläther als opioid-rezeptor antagonisten
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
ATE406360T1 (de) 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
US7196100B2 (en) 2003-12-12 2007-03-27 Eli Lilly And Company Opioid receptor antagonists
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
US7288543B2 (en) 2004-03-12 2007-10-30 Eli Lilly And Company Opioid receptor antagonists
WO2005090286A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
CA2559207A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
ES2318472T3 (es) 2004-03-15 2009-05-01 Eli Lilly And Company Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad.
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
ES2337622T3 (es) 2006-04-04 2010-04-27 Emodys Gmbh Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2064199A1 (en) 2006-09-08 2009-06-03 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
EP2252581B1 (en) * 2008-01-22 2012-06-20 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
WO2009094260A1 (en) 2009-07-30
KR101172170B1 (ko) 2012-08-07
PL2252581T3 (pl) 2012-10-31
NZ586225A (en) 2012-05-25
US20090186873A1 (en) 2009-07-23
IL206038A0 (en) 2010-11-30
MY163014A (en) 2017-07-31
JP2011524850A (ja) 2011-09-08
CY1113071T1 (el) 2016-04-13
US7709522B2 (en) 2010-05-04
BRPI0907382A2 (pt) 2015-07-21
ES2388708T3 (es) 2012-10-17
TWI422369B (zh) 2014-01-11
PE20091317A1 (es) 2009-09-03
AR070158A1 (es) 2010-03-17
US20100197669A1 (en) 2010-08-05
CO6290644A2 (es) 2011-06-20
TN2010000306A1 (en) 2011-11-11
CN101925576B (zh) 2013-02-06
KR20100095639A (ko) 2010-08-31
ZA201003908B (en) 2011-11-30
TW200936129A (en) 2009-09-01
DK2252581T3 (da) 2012-07-16
BRPI0907382B8 (pt) 2021-05-25
CN101925576A (zh) 2010-12-22
HRP20120558T1 (hr) 2012-10-31
PT2252581E (pt) 2012-08-31
MX2010007849A (es) 2010-08-09
AU2009206653B2 (en) 2013-07-18
EA201070877A1 (ru) 2010-12-30
JO2797B1 (en) 2014-03-15
AU2009206653A1 (en) 2009-07-30
UA100715C2 (ru) 2013-01-25
ECSP10010365A (es) 2010-08-31
EP2252581B1 (en) 2012-06-20
CA2713025A1 (en) 2009-07-30
CA2713025C (en) 2012-12-04
US8173695B2 (en) 2012-05-08
DOP2010000222A (es) 2015-11-15
BRPI0907382B1 (pt) 2020-03-10
EA017484B1 (ru) 2012-12-28
JP5345637B2 (ja) 2013-11-20
MA32751B1 (fr) 2011-11-01
SI2252581T1 (sl) 2012-09-28
EP2252581A1 (en) 2010-11-24
IL206038A (en) 2013-11-28

Similar Documents

Publication Publication Date Title
HK1146822A1 (en) Kappa selective opioid receptor antagonist kappa
EP2252150A4 (en) SELECTIVE OPIOID COMPOUNDS
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
EP2034832A4 (en) IL-8 RECEPTOR ANTAGONIST
EP2244575A4 (en) ANTAGONISTS OF THE ANGIOTENSIN II RECEPTOR
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
ZA201203452B (en) Cgrp receptor antagonists
IL212551A0 (en) Cxcr4 receptor compounds
EP2387577A4 (en) STRONG AND SELECTIVE NON-PEPTIDYL MU OPIOID RECEPTOR ANTAGONISTS
ZA200808358B (en) IL-8 receptor antagonists
IL213112A0 (en) Nalmefene hydrochloride dihydrate
IL194700A0 (en) Il-8 receptor antagonists
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
EP2099300A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
EP2296469A4 (en) KAPPA OPIOID RECEPTOR LIGANDS
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
HK1149205A1 (en) Methods for inhibiting angiogenesis using egfl8 antagonists
EP2539706A4 (en) ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
EP2341919A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2340025A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2250168A4 (en) ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
EP2291076A4 (en) Angiotensin-II Receptor Antagonists